Boston Scientific forecasts Q4 2026 net sales decline of 1%-3%
BSX•Boston Scientific expects fourth-quarter 2026 reported and organic sales to decline 1%-3% year over year, with adjusted earnings of $0.77-$0.79 per share. It forecasts full-year adjusted earnings of $3.16-$3.18 per share and annual reported sales growth of about 4.25%.
1. 2026 outlook
Boston Scientific forecasts fourth-quarter 2026 reported and organic sales will decline 1%-3% year over year, and adjusted earnings will be $0.77-$0.79 per share. For full-year 2026, it projects adjusted earnings of $3.16-$3.18 per share, reported sales growth of approximately 4.25% and organic sales growth of approximately 3.75%.
2. Third-quarter sales
Third-quarter 2026 sales rose 1.5% to $5.14 billion, with several businesses affected by a cyber incident.
